Pimavanserin tartrate is primarily used in the treatment of Parkinson’s disease psychosis (PDP), a condition where patients experience hallucinations and delusions. It works by selectively blocking serotonin receptors in the brain, which helps reduce these symptoms without worsening motor function, a common concern with other antipsychotics. This makes it a valuable option for patients who need to manage psychosis while maintaining their motor capabilities. Additionally, it is being investigated for potential use in other psychiatric conditions, such as Alzheimer’s disease-related psychosis and major depressive disorder, due to its unique mechanism of action. Its ability to target specific receptors minimizes side effects often associated with traditional antipsychotics, offering a more tailored approach to treatment.